Table 2 Comparison of PFS/TTNT from real-world reports and phase 3 clinical studies in RRMM patients after 1–3 prior lines of therapy; see Supplementary Table S4 for full details of studies cited for each range/piece of data

From: Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

Regimens

Phase 3 clinical studies

Real-world reports

All reports identified

Studies/registry analysesa

EMR/chart review/claims analysesb

All regimens combined

Not applicable

6–15.1

6.4–14.1

6–15.1

PI doublet / PI-basedc

Btz: 6.2–9.4 Cfz: 14.9–22.2

Btz: 5.7–11.9 Cfz: 3.2–10.6

Btz: 5.7–11.3 Cfz: 5.6–10.6

Btz: 6.9–11.9 Cfz: 3.2–9.4

PI-alkylator triplet

12–18.4d

6.5–16.2

NR

6.5–16.2

Injectable PI-immunomodulatory drug triplet

18.3–29.6

9.4–25.3

NR

9.4–25.3

Oral PI-immunomodulatory drug triplet

17.5–20.6

19.2–27.6

27.6

19.2

Len doublet / len-basedc

11.1–18.4

6.6–21

6.6–8.7

7–21

  1. Note: Data shown are ranges of median PFS/TTNT (months) reported from multiple studies/analyses
  2. aIncluding prospective and retrospective registry studies and observational studies, and analyses of data from named patient programs/compassionate use programs
  3. bIncluding single-center, retrospective chart reviews, EMR reviews, longitudinal chart reviews
  4. cRegimen not specified beyond ‘PI-based’ or ‘len-based’ in some real-world reports
  5. dData from two phase 2 studies of VCd
Back to article page